United Therapeutics Co. (UTHR) Director Tommy G. Thompson Sells 400 Shares

United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson sold 400 shares of the stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $117.00, for a total value of $46,800.00. Following the completion of the sale, the director now directly owns 2,970 shares in the company, valued at $347,490. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of UTHR stock opened at $116.95 on Wednesday. The company has a current ratio of 4.32, a quick ratio of 4.05 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a twelve month low of $100.06 and a twelve month high of $139.54. The company has a market capitalization of $5.09 billion, a P/E ratio of 10.74, a P/E/G ratio of 44.01 and a beta of 1.05.

UTHR has been the topic of several analyst reports. Cowen set a $106.00 target price on United Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, October 31st. Credit Suisse Group raised their price target on United Therapeutics from $103.00 to $105.00 and gave the company a “sell” rating in a report on Monday, November 19th. BidaskClub lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 31st. Oppenheimer set a $160.00 price target on United Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 20th. Finally, HC Wainwright reissued a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a report on Thursday, November 1st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. United Therapeutics presently has a consensus rating of “Hold” and an average price target of $134.00.

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its position in United Therapeutics by 2.8% in the 2nd quarter. Bank of America Corp DE now owns 99,674 shares of the biotechnology company’s stock worth $11,277,000 after buying an additional 2,724 shares during the period. Northern Trust Corp grew its holdings in shares of United Therapeutics by 2.7% during the 2nd quarter. Northern Trust Corp now owns 443,163 shares of the biotechnology company’s stock worth $50,145,000 after purchasing an additional 11,655 shares in the last quarter. Fox Run Management L.L.C. grew its holdings in shares of United Therapeutics by 85.2% during the 3rd quarter. Fox Run Management L.L.C. now owns 4,406 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 2,027 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of United Therapeutics by 4.3% during the 3rd quarter. Bank of Montreal Can now owns 66,930 shares of the biotechnology company’s stock worth $8,559,000 after purchasing an additional 2,779 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in shares of United Therapeutics by 18.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 17,535 shares of the biotechnology company’s stock worth $2,242,000 after purchasing an additional 2,685 shares in the last quarter. 97.61% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first published by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://theenterpriseleader.com/2019/02/06/united-therapeutics-co-uthr-director-tommy-g-thompson-sells-400-shares.html.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also: What is the Bid-Ask Spread?

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.